Why Eledon Pharmaceuticals, Inc.’s (ELDN) Stock Is Down 5.46%
As of Tuesday, July 28, Eledon Pharmaceuticals, Inc.’s ELDN share price has dipped by 5.46%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Commentary & Analysis
Why Eledon Pharmaceuticals, Inc.’s (ELDN) Stock Is Down 6.23%
As of Friday, July 10, Eledon Pharmaceuticals, Inc.’s ELDN share price has dipped by 6.23%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Eledon Pharmaceuticals, Inc.’s (ELDN) Stock Is Up 7.48%
As of Tuesday, June 23, Eledon Pharmaceuticals, Inc.’s ELDN share price has surged by 7.48%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Eledon Pharmaceuticals, Inc.’s (ELDN) Stock Is Up 6.07%
As of Monday, June 22, Eledon Pharmaceuticals, Inc.’s ELDN share price has surged by 6.07%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Eledon Pharmaceuticals, Inc.’s (ELDN) Stock Is Up 5.81%
As of Thursday, June 18, Eledon Pharmaceuticals, Inc.’s ELDN share price has surged by 5.81%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ELDN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $261.3 | $252.6 | 30% |
|
| Shares Out (Mil) | 112.5 | 52.3 | 65% |
|
| Institutional Ownership | 99.9% | 92.1% | 96% |
|
| Float (Mil) | 70.8 | 40.2 | 55% |
|
| Beta | 0.96 | 0.95 | 57% |
|
| Avg Daily Volume (000s) | 1,005 | 455 | 71% |
|
| Price Change (52-week) |
7.0% | 52.9% | 51% |
|
| Growth | ELDN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (14.9%) | (9.9%) | 25% |
|
| EPS (5yr) | 48.7% | 16.0% | 92 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (79.0%) | (15.6%) | 1% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 3 | |
| Current EPS | ($0.153) | ($0.873) | ($0.723) | |
| Month Ago EPS | ($0.153) | ($0.873) | ($0.723) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.240) | ($0.955) | ($0.803) | |
| Year/Year Chg | (55.9%) | 56.7% | 32.9% | |
| Financials | ELDN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($78) | ($43) | 13% |
|
| EPS (TTM) | ($0.861) | ($1.600) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($69) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 12% |
|
| Enterprise Value (Q1) (Mil) | $200 | $180 | 26% |
|
| Valuation | ELDN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.56 | 2.56 | 60% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ELDN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (50.7%) | (49.8%) | 12% |
|
| ROE | (98.1%) | (55.5%) | 10% |
|
| Liabilities to Assets | 31.5% | 30.3% | 22% |
|
| F-Score | 2 | 3 | 7% |
|
Eledon Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
